NO994837L - Intravesikal medikamentavleveringssystem - Google Patents

Intravesikal medikamentavleveringssystem

Info

Publication number
NO994837L
NO994837L NO994837A NO994837A NO994837L NO 994837 L NO994837 L NO 994837L NO 994837 A NO994837 A NO 994837A NO 994837 A NO994837 A NO 994837A NO 994837 L NO994837 L NO 994837L
Authority
NO
Norway
Prior art keywords
delivery system
drug delivery
intravesical drug
intravesical
drug
Prior art date
Application number
NO994837A
Other languages
English (en)
Norwegian (no)
Other versions
NO994837D0 (no
Inventor
Thomas B Ottoboni
Ronald K Yamamoto
Stanley R Conston
Original Assignee
Point Biomedical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Point Biomedical Corp filed Critical Point Biomedical Corp
Publication of NO994837D0 publication Critical patent/NO994837D0/no
Publication of NO994837L publication Critical patent/NO994837L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO994837A 1997-04-03 1999-10-04 Intravesikal medikamentavleveringssystem NO994837L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83324797A 1997-04-03 1997-04-03
PCT/US1998/006445 WO1998043555A1 (fr) 1997-04-03 1998-04-02 Systeme intravesical de liberation de medicaments

Publications (2)

Publication Number Publication Date
NO994837D0 NO994837D0 (no) 1999-10-04
NO994837L true NO994837L (no) 1999-11-10

Family

ID=25263865

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994837A NO994837L (no) 1997-04-03 1999-10-04 Intravesikal medikamentavleveringssystem

Country Status (10)

Country Link
US (3) US6039967A (fr)
EP (1) EP0971641A4 (fr)
JP (1) JP2001519787A (fr)
KR (1) KR20010006027A (fr)
AU (1) AU6876498A (fr)
CA (1) CA2285591A1 (fr)
DE (1) DE19882286T1 (fr)
GB (1) GB2338414B (fr)
NO (1) NO994837L (fr)
WO (1) WO1998043555A1 (fr)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US6623751B2 (en) * 1998-07-30 2003-09-23 L'oreal S.A. Cosmetic, pharmaceutical, or dermatological patch
US6293923B1 (en) 1999-03-15 2001-09-25 Innoventions, Inc. Intravesicular balloon
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
EP1949890A3 (fr) * 1999-06-04 2011-05-18 ALZA Corporation Compositions de gel implantables et procédé de fabrication
HUP0201626A3 (en) * 1999-06-04 2004-05-28 Alza Corp Mountain View Implantable gel compositions and method of manufacture
US6740039B1 (en) 1999-08-20 2004-05-25 Koninklijke Philips Electronics N.V. Methods and apparatus for displaying information relating to delivery and activation of a therapeutic agent using ultrasound energy
US6527718B1 (en) 1999-08-20 2003-03-04 Brian G Connor Ultrasound system for continuous imaging and delivery of an encapsulated agent
JP2003531157A (ja) * 2000-04-26 2003-10-21 ワトソン ファーマシューティカルズ， インコーポレイテッド オキシブチニン治療に関連した有害な経験の最小化
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US6398718B1 (en) 2000-06-15 2002-06-04 Innoventions, Inc. Intravesicular device
US6545046B2 (en) 2000-08-30 2003-04-08 Theramax Inc. Method for enhanced delivery of oxybutynin and compositions thereof
US6699665B1 (en) * 2000-11-08 2004-03-02 Surface Logix, Inc. Multiple array system for integrating bioarrays
US6558312B2 (en) 2001-03-13 2003-05-06 Clemson University Intraurethral device for incontinence
WO2002071922A2 (fr) * 2001-03-13 2002-09-19 Clemson University Dispositif intra-uretral permettant de traiter ou de detecter differentes maladies et infections du systeme urinaire
KR100426636B1 (ko) * 2001-05-18 2004-04-08 한국과학기술연구원 주사 가능한 젤 상의 조성물 및 그의 제조방법
US6702744B2 (en) * 2001-06-20 2004-03-09 Advanced Cardiovascular Systems, Inc. Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery
US8110217B2 (en) * 2001-08-13 2012-02-07 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
WO2003015698A2 (fr) * 2001-08-13 2003-02-27 University Of Pittsburgh Application de vehicules lipidiques et utilisation dans le cadre de l'administration de medicaments
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US6878693B2 (en) 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US6893431B2 (en) 2001-10-15 2005-05-17 Scimed Life Systems, Inc. Medical device for delivering patches
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
PT2060259E (pt) * 2001-11-01 2010-04-26 Spectrum Pharmaceuticals Inc Composições médicas para o tratamento intravesical do cancro da bexiga
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
US8608661B1 (en) 2001-11-30 2013-12-17 Advanced Cardiovascular Systems, Inc. Method for intravascular delivery of a treatment agent beyond a blood vessel wall
US8685427B2 (en) * 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
US8133501B2 (en) * 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US7361368B2 (en) 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
US8920826B2 (en) * 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
US7149874B2 (en) * 2002-08-16 2006-12-12 Micron Technology, Inc. Memory hub bypass circuit and method
JP2006506385A (ja) * 2002-10-22 2006-02-23 ザ バイオメリックス コーポレーション 治療剤を小嚢内デリバリーするための方法およびシステム
US7597903B2 (en) * 2002-12-02 2009-10-06 Shenkar College Of Engineering And Design Method and composition for producing catheters with antibacterial property
US20060058777A1 (en) * 2002-12-11 2006-03-16 Pia Norup Nielsen Urinary catheter device with a pharmaceutically active composition
JP2004246317A (ja) * 2002-12-20 2004-09-02 Hitachi Ltd 冷陰極型フラットパネルディスプレイ
US7544192B2 (en) 2003-03-14 2009-06-09 Sinexus, Inc. Sinus delivery of sustained release therapeutics
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8038991B1 (en) 2003-04-15 2011-10-18 Abbott Cardiovascular Systems Inc. High-viscosity hyaluronic acid compositions to treat myocardial conditions
US8383158B2 (en) 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
CA2525792C (fr) 2003-05-15 2015-10-13 Biomerix Corporation Matrices elastomeres reticulees, leur production et leur utilisation dans des dispositifs implantables
US20040249364A1 (en) * 2003-06-03 2004-12-09 Ilya Kaploun Device and method for dispensing medication to tissue lining a body cavity
US20060177497A1 (en) * 2003-07-21 2006-08-10 Bio Dar Ltd. Gellan gum based oral controlled release dosage forms-a novel platform technology for gastric retention
NZ528648A (en) 2003-10-02 2005-08-26 Agres Ltd Altering animal waste composition
US20050175709A1 (en) * 2003-12-11 2005-08-11 Baty Ace M.Iii Therapeutic microparticles
US7763077B2 (en) 2003-12-24 2010-07-27 Biomerix Corporation Repair of spinal annular defects and annulo-nucleoplasty regeneration
WO2006013851A1 (fr) * 2004-08-03 2006-02-09 Nippon Shinyaku Co., Ltd. Dispositif a utiliser dans une cavite du corps et preparation a liberation continue
US8361490B2 (en) * 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
US7854944B2 (en) 2004-12-17 2010-12-21 Advanced Cardiovascular Systems, Inc. Tissue regeneration
CA2603081C (fr) 2005-04-04 2013-09-03 Sinexus, Inc. Dispositifs et procedes de traitement des affections sinus paranasaux
US20080125745A1 (en) * 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US8187621B2 (en) * 2005-04-19 2012-05-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treating post-myocardial infarction damage
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US8303972B2 (en) * 2005-04-19 2012-11-06 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US9346029B2 (en) 2005-06-06 2016-05-24 The University Of British Columbia Polymer-based serum albumin substitute
US8801694B2 (en) * 2005-08-11 2014-08-12 Massachusetts Institute Of Technology Intravesical drug delivery device
US7732190B2 (en) * 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
WO2008035172A2 (fr) * 2006-09-18 2008-03-27 Glenmark Pharmaceuticals Limited Composition pharmaceutique contenant de la desmopressine
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8741326B2 (en) * 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
US8702591B2 (en) * 2007-01-12 2014-04-22 Olympus Medical Systems Corp. Capsule medical apparatus
US20080161639A1 (en) * 2006-12-28 2008-07-03 Olympus Medical Systems Corporation Capsule medical apparatus and body-cavity observation method
DE102007003765A1 (de) * 2007-01-19 2008-07-24 Farco-Pharma Gmbh Pharmazeutische Zusammensetzung zur Behandlung von Inkontinenz
BRPI0820800B8 (pt) 2007-12-11 2021-06-22 Massachusetts Inst Technology dispositivo médico implantável para liberação controlada de droga
DK2231065T3 (da) 2007-12-18 2021-02-01 Intersect Ent Inc Selvekspanderende anordninger
CA2732355A1 (fr) 2008-08-01 2010-02-04 Intersect Ent, Inc. Procedes et dispositifs pour sertir des dispositifs auto-dilatables
JP5908279B2 (ja) * 2008-08-09 2016-04-26 マサチューセッツ インスチテュート オブ テクノロジーＭａｓｓａｃｈｕｓｅｔｔｓ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｔｅｃｈｎｏｌｏｇｙ 移植可能な薬物送達デバイス並びに男性の尿生殖器及び周囲組織を治療する方法
US20100291182A1 (en) * 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
AU2010246296A1 (en) 2009-04-28 2011-11-03 Ams Research Corporation Biologic treatment system and method
JP2012526133A (ja) 2009-05-05 2012-10-25 ベイポジェニックス インコーポレイテッド 炎症を低減させるための新規揮発性麻酔薬製剤およびその使用法
EP3103502A1 (fr) 2009-05-15 2016-12-14 Intersect ENT, Inc. Dispositifs expansibles et procédés associés
CN101724163B (zh) * 2009-06-23 2011-09-07 河南科技大学 一种壳聚糖衍生物复合微球及其制备方法和应用
ES2401008T3 (es) 2009-06-26 2013-04-16 Taris Biomedical, Inc. Comprimidos farmacéuticos sólidos para dispositivos implantables para la administración de fármacos
DE102009035586A1 (de) 2009-07-31 2011-02-03 Fresenius Kabi Deutschland Gmbh Intravesikale Instillationslösungen zur Behandlung von Blasenkrebs
US9173817B2 (en) 2009-08-24 2015-11-03 Arsenal Medical, Inc. In situ forming hemostatic foam implants
US10420862B2 (en) 2009-08-24 2019-09-24 Aresenal AAA, LLC. In-situ forming foams for treatment of aneurysms
US20110202016A1 (en) * 2009-08-24 2011-08-18 Arsenal Medical, Inc. Systems and methods relating to polymer foams
US9044580B2 (en) 2009-08-24 2015-06-02 Arsenal Medical, Inc. In-situ forming foams with outer layer
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
AU2015201123B2 (en) * 2009-12-17 2016-04-21 Taris Biomedical Llc Implantable device with intravesical tolerability and methods of treatment
PT2512581T (pt) * 2009-12-17 2021-04-27 Taris Biomedical Inc Dispositivo implantável com tolerabilidade intravesical e métodos de tratamento
ES2732150T3 (es) 2010-01-20 2019-11-20 Urogen Pharma Ltd Material y método para tratar cavidades internas
CN106432747B (zh) 2010-03-01 2019-11-05 不列颠哥伦比亚大学 衍生的超支化聚丙三醇
HUE051942T2 (hu) 2010-08-05 2021-03-29 Taris Biomedical Llc Implantálható gyógyszerszállító készülékek genitourinális szervekhez
US8690840B2 (en) 2010-10-06 2014-04-08 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
ES2943334T3 (es) 2011-01-10 2023-06-12 Taris Biomedical Llc Régimen de lidocaína para el uso de tratamiento sostenido del dolor de vejiga y micción irritativa
US9034240B2 (en) 2011-01-31 2015-05-19 Arsenal Medical, Inc. Electrospinning process for fiber manufacture
US8968626B2 (en) 2011-01-31 2015-03-03 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
US9194058B2 (en) 2011-01-31 2015-11-24 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
BR112013019410A2 (pt) 2011-02-04 2019-09-24 Taris Biomedical Inc dispositivo implantável para liberação controlada de fármaco de solubilidade baixa
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
EP2734187B1 (fr) 2011-07-20 2018-09-05 UroGen Pharma Ltd. Matériaux et méthode de traitement de cavités corporelles internes
CA2853279C (fr) 2011-10-24 2021-03-23 Endo Pharmaceuticals Inc. Cyclohexylamines
US8993831B2 (en) 2011-11-01 2015-03-31 Arsenal Medical, Inc. Foam and delivery system for treatment of postpartum hemorrhage
US10857336B2 (en) 2012-05-19 2020-12-08 Taris Biomedical Llc Implantable urological device with improved retrieval feature
EP3636227B1 (fr) 2013-03-14 2024-08-28 Intersect ENT, Inc. Systèmes et dispositifs de traitement d'une affection sinusale
KR102398262B1 (ko) 2013-03-15 2022-05-13 타리스 바이오메디컬 엘엘씨 약물-투과성 구성요소를 가지는 약물 전달 장치 및 방법
EP3736015B1 (fr) 2013-08-19 2023-06-28 TARIS Biomedical LLC Dispositifs d'administration de médicament à unités multiples
BR112016013734A2 (pt) 2013-12-16 2017-08-08 Asana Biosciences Llc Composto, composição farmacêutica, kit, e uso de um composto
CN103861091B (zh) * 2014-03-20 2016-04-27 辽宁亿灵科创生物医药科技有限公司 治疗膀胱炎的药物组合物
EP3517099B1 (fr) 2014-06-26 2022-12-28 TARIS Biomedical LLC Dispositifs d'administration de médicaments intravésicaux et procédés comprenant des systèmes de matrice médicament-polymère élastique
CZ308594B6 (cs) * 2014-09-29 2020-12-23 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Mukoadhezivní nosiče částic, způsob přípravy a použití
CN113679931A (zh) 2015-01-22 2021-11-23 因特尔赛克特耳鼻喉公司 药物涂覆的气囊
JP7425534B2 (ja) 2015-04-23 2024-01-31 タリス バイオメディカル エルエルシー 薬物透過性構成要素を有する薬物送達デバイス及び方法
MX2019003710A (es) 2016-09-30 2019-06-24 Asana Biosciences Llc Compuestos y metodos de p2x3 y/o p2x2/3.
IT201700104446A1 (it) 2017-09-19 2019-03-19 Lo Li Pharma Srl Compositions, uses and methods for treatment of infertility and subfertility
BR112020012687A2 (pt) 2017-12-22 2020-11-24 Lo.Li. Pharma International S.R.L. uso de inositol
WO2020069376A1 (fr) * 2018-09-27 2020-04-02 Watershed Medical, Inc. Dispositif et procédé de traitement d'infections
US20220107320A1 (en) 2019-02-15 2022-04-07 Incelldx, Inc. Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
IT201900003843A1 (it) 2019-03-15 2020-09-15 Lo Li Pharma Srl Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG)
CA3138433A1 (fr) * 2019-04-30 2020-11-05 Trigone Pharma Ltd. Formulations et procedes d'instillation de medicament dans la vessie et de traitement de maladies de la vessie
WO2021067857A1 (fr) 2019-10-02 2021-04-08 Watershed Medical, Inc. Dispositif et méthode d'amélioration de rétention d'une thérapie dans la vessie
WO2023205704A1 (fr) * 2022-04-19 2023-10-26 Watershed Medical, Inc. Méthode de traitement de troubles du système urinaire
IT202200013867A1 (it) 2022-06-30 2023-12-30 Lo Li Pharma Srl Composizione per il trattamento dell’ infezione da papilloma virus (hpv)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2961374A (en) * 1950-10-14 1960-11-22 Lieb Hans Injectable pharmaceutical preparation, and a method of making same
JPS51140582A (en) * 1975-05-30 1976-12-03 Nec Corp Semiconductor resistance element
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US4871542A (en) * 1987-04-30 1989-10-03 Ferring Service Center, N.V. Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract
FR2657018A1 (fr) * 1990-01-12 1991-07-19 Merck Sharp & Dohme Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation.
WO1991017745A1 (fr) * 1990-05-23 1991-11-28 Southwest Research Institute Systeme a filament d'acheminement d'un medicament et procede
ES2150427T3 (es) * 1992-06-02 2000-12-01 Bard Inc C R Procedimiento y dispositivo de implante para el suministro de farmacos a largo plazo.

Also Published As

Publication number Publication date
US6207180B1 (en) 2001-03-27
GB2338414A (en) 1999-12-22
GB2338414B (en) 2001-12-19
EP0971641A4 (fr) 2003-08-13
EP0971641A1 (fr) 2000-01-19
US20010019719A1 (en) 2001-09-06
US6524608B2 (en) 2003-02-25
GB9923410D0 (en) 1999-12-08
KR20010006027A (ko) 2001-01-15
AU6876498A (en) 1998-10-22
NO994837D0 (no) 1999-10-04
DE19882286T1 (de) 2000-04-27
JP2001519787A (ja) 2001-10-23
CA2285591A1 (fr) 1998-10-08
US6039967A (en) 2000-03-21
WO1998043555A1 (fr) 1998-10-08

Similar Documents

Publication Publication Date Title
NO994837L (no) Intravesikal medikamentavleveringssystem
DE69832055D1 (de) Transdermales abgabesystem
ATE291417T1 (de) Gastrointestinales wirkstoffverabreichungssystem
DE69923076D1 (de) Transthorakale arzneimittelabgabevorrichtung
EE9800025A (et) Transkorneaalne süsteem ravimite manustamiseks
ID23874A (id) Obat
DE69822529D1 (de) Stentanbringungssystem
EE200000546A (et) Aerosoolistatud toimeaine manustamissüsteem
DE69711045D1 (de) Vitamin c abgabesystem
DE59701787D1 (de) Medikamenten-dosiersystem
DE60016271D1 (de) Medikamentenzuführvorrichtung
DE69823583D1 (de) Kassette und Kassetenliefersystem
NO20004196D0 (no) Innretninger for legemiddelavlevering
BR9801027B1 (pt) sistema de distribuiÇço de medicamentos.
DE69502216D1 (de) Zweikomponenten Abgabesystem
DE69531788D1 (de) Verbessertes bioadhäsives pharmazeutisches abgabesystem
DE69821457D1 (de) Zusammensetzungen mit kontrollierter Wirkstoffabgabe
NO980546D0 (no) Farmasöytiske midler
EP1061987A4 (fr) Dispositif servant a administrer un medicament
DE69810189D1 (de) Zusammensetzungen mit kontrollierter Wirkstoffabgabe
EP0989878A4 (fr) Systeme d'administration de medicaments
AU7201998A (en) Drug delivery system
EP1021137A4 (fr) Systeme d'administration de medicaments
DE69740133D1 (de) Patiententransportsystem
DE59902337D1 (de) Fadenliefersystem

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application